Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I am a long-term myeloma survivor and myeloma coach. I’m writing this post for the benefit of myeloma patients, survivors and caregivers. According to two of the studies linked and excerpted below, Agaricus blazei Murrill (ABM) aka medical mushrooms are the ultimate multiple myeloma therapy.
These mushroom are both cytotoxic to MM and can moderate the side effects of high-dose therapies such as an autologous stem cell transplant (ASCT).
I included studies below that cite the cytotoxic property of about UC, Crohn’s and Intestinal cancer mainly to fortify the idea that Agaricus blazei Murrill show many positive health effects.
I have no personal experience with Agaricus blazei Murrill mushrooms. My approach is that of a long-term MM survivor who acknowledges that conventional oncology considers MM to be incurable.
If MM patients and survivors confine themselves to conventional MM therapies they will eventually confront multi-drug resistance and run out of options.
To put it another way, MM patients and survivors can reduce their reliance on toxic therapies by including evidence-based MM therapies.
According to the studies below, ABM:
I have linked a well-reviewed ABM product from Amazon though it is not the product of the studies called AndoSan™.
“Conclusion- The study showed evidence of a number of immunomodulating effects of AndoSan, used as adjuvant therapy to the high dose of melphalan with autologous stem cell support in patients with multiple myeloma, which possibly may have a clinical significance. However, the results must be interpreted with caution because of the restricted sample size of the study. No statistically significant clinical impact of AndoSan was detected, although trends for a longer median time to next treatment (37.5 months versus 31.2 months) and a shorter period of i.v. antibiotics (8.6 days versus 10.0 days) were noted in the Agaricus group…”
“Agaricus blazei Murrill is an edible mushroom of the Basidiomycetes family, which has been found to contain a number of compounds with antitumor properties, such as proteoglycans and ergosterol. In the present investigation, we show that the commercial mushroom product Andosan, which contains 82.4% Agaricus blazeiMurill, together with medicinal mushrooms Hericium erinaceus (14.7%) and Grifola frondosa (2.9%), has a cytotoxic effect on primary myeloma cells, other myeloma cell lines, and leukemia cell lines in vitro…
This study shows a predominantly dose-related cytotoxic effect of Andosan on primary myeloma cells and human myeloma and leukemic cell lines in vitro. These results are in line with previous reports of cytotoxic effects of different compounds (β– glucans, proteoglycans, ergosterol, and agaritine) extracted from AbM preparations from the fruiting body, on different malignant tumors, both in vitro and in animal models [14–20].
In particular, it has been shown that an extract of the fruiting body of Agaricus blazei Murill had an antitumor effect in a mouse myeloma model when given together with a marine phospholipid . In the case of Andosan, which is a commercial mushroom extract where the exact content is not known, a firm conclusion regarding the mechanism behind the cytotoxic effects is not possible.
However, it is remarkable that indications of cell cycle arrest were found when the myeloma cell lines RPMI-8226, U226, and INA-6 were cultivated with Andosan. We and others [19, 20, 22] have previously found that AbM extracts can have cytotoxic effects on tumor cells by induction of apoptosis. Also, it has been documented that an ethanol-soluble fraction of Andosan inhibits the tumor-associated protease legumain in the murine macrophage-like cell line RAW 264.7 .
This may indirectly indicate an antitumor effect of this fraction, as legumain is secreted by a number of malignant cells . In fact, in the mouse model for colon cancer, Andosan did also induce reduced expression of legumain in the intestinal wall . Moreover, it increased levels of Th1 cytokine IL-12 in addition to proinflammatory cytokines . The latter is in contrast to what we have usually observed in humans consuming Andosan. However, it agrees with our previous in vitro finding of Andosan-induced -B activation via stimulation of TLR2 in dendritic cells .
Furthermore, the possibility of a synergistic effect between the three mushrooms contained in Andosan—Agaricus blazei Murill, Grifola frondosa, and Hericium erinaceus—may also be taken into consideration. Importantly, Andosan did not have a toxic effect neither on human peripheral mononuclear cells (PMNC) nor on normal human hematopoietic stem cells (G. Hetland et al., unpublished results).
The cytotoxic effects of Andosan found in this investigation on primary myeloma cells and myeloma cell lines are particularly interesting in light of the previously reported immunomodulating effects mostly associated with antitumor properties when this product was used as an adjuvant treatment in myeloma patients undergoing high-dose chemotherapy . It, therefore, seems plausible that the mushroom extract may have both cytotoxic and immunomodulating antitumor mechanisms of action in myeloma. Further investigations are needed in order to clarify whether Andosan may have a role in the treatment of multiple myeloma.
“Beneficiary effects on symptoms, fatigue, and HRQoL from AndoSan™ consumption were demonstrated in this per-protocol study, supporting its use as a supplement to conventional medication for patients with mild to moderate symptoms from ulcerative colitis. The patients did not report any harms or unintended effects of AndoSan™ in this study.”
“The results from this single-blinded randomized clinical trial shows significant improvement in symptoms, for both gendshowin the AndoSanTM group, but no significant differences between the study groups…”
“The results from this mouse model for colorectal cancer show significant protection of orally administered Andosan™ against the development of intestinal cancer…”